Barclays PLC Purchases 84,136 Shares of Organon & Co. (NYSE:OGN)

Barclays PLC boosted its position in Organon & Co. (NYSE:OGN) by 238.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 119,483 shares of the company’s stock after buying an additional 84,136 shares during the period. Barclays PLC’s holdings in Organon & Co. were worth $2,285,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Mercer Global Advisors Inc. ADV raised its position in shares of Organon & Co. by 1.8% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock worth $674,000 after acquiring an additional 546 shares in the last quarter. Ballentine Partners LLC increased its stake in shares of Organon & Co. by 3.0% in the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock valued at $395,000 after acquiring an additional 552 shares in the last quarter. Sippican Capital Advisors lifted its position in shares of Organon & Co. by 4.3% during the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock valued at $291,000 after acquiring an additional 627 shares during the period. Commerce Bank boosted its stake in Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after acquiring an additional 637 shares in the last quarter. Finally, Signaturefd LLC grew its holdings in Organon & Co. by 6.6% in the second quarter. Signaturefd LLC now owns 11,308 shares of the company’s stock worth $234,000 after purchasing an additional 698 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

OGN stock opened at $14.73 on Thursday. The company has a market capitalization of $3.79 billion, a P/E ratio of 2.92, a price-to-earnings-growth ratio of 0.81 and a beta of 0.75. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 52-week low of $13.65 and a 52-week high of $23.10. The business has a 50-day simple moving average of $15.92 and a two-hundred day simple moving average of $18.83.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the business earned $0.78 EPS. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. Research analysts expect that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were paid a $0.28 dividend. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 annualized dividend and a dividend yield of 7.60%. Organon & Co.’s payout ratio is 22.22%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price target for the stock from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.